Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Relay Therapeutics (RLAY) over the last 6 years, with Q2 2025 value amounting to 11351.11%.

  • Relay Therapeutics' EBIT Margin changed N/A to 11351.11% in Q2 2025 from the same period last year, while for Sep 2025 it was 3914.38%, marking a year-over-year decrease of 1198100.0%. This contributed to the annual value of 3722.07% for FY2024, which is 22619600.0% down from last year.
  • Per Relay Therapeutics' latest filing, its EBIT Margin stood at 11351.11% for Q2 2025.
  • Relay Therapeutics' 5-year EBIT Margin high stood at 9219600.0% for Q4 2023, and its period low was 89117.65% during Q2 2023.
  • Its 5-year average for EBIT Margin is 595567.98%, with a median of 11944.09% in 2021.
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by 2000000000bps in 2021, then soared by 2000000000bps in 2023.
  • Quarter analysis of 5 years shows Relay Therapeutics' EBIT Margin stood at 11944.09% in 2021, then crashed by -141bps to 28794.86% in 2022, then surged by 32118bps to 9219600.0% in 2023, then plummeted by -100bps to 903.0% in 2024, then tumbled by -1157bps to 11351.11% in 2025.
  • Its EBIT Margin stands at 11351.11% for Q2 2025, versus 1105.21% for Q1 2025 and 903.0% for Q1 2024.